CureGene reports preclinical weight loss data for CG-0416 at Obesity Week 2026
CureGene presented preclinical findings indicating that its oral drug candidate CG-0416 enhanced weight loss and reduced weight regain when paired with reduced-dose GLP-1 receptor agonists.

CureGene unveiled new preclinical data for its oral therapeutic candidate, CG-0416, during the Obesity Week 2026 conference. The findings suggest the compound may serve as a complementary agent to existing weight-management therapies.
According to the study results, subjects administered a combination of CG-0416 and a lower-than-standard dose of a GLP-1 receptor agonist achieved more significant weight reduction than those on the agonist alone. Furthermore, the data showed a slower rate of weight regain following the cessation of the GLP-1 treatment, suggesting a potential maintenance benefit.
While the market for obesity treatments is currently dominated by high-profile injectable GLP-1 drugs, companies are increasingly focusing on oral alternatives and combination therapies to improve tolerability and long-term outcomes. CureGene’s data represents an early-stage attempt to address the challenges of dose-related side effects and weight regain cycles.
The findings remain at the preclinical stage. CureGene has not yet disclosed a timeline for human clinical trials or regulatory milestones for the CG-0416 program.